High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab

被引：0
|
作者：
Kjeldsen, Julie W. [1 ]
Lorentzen, Cathrine L. [1 ]
Martinenaite, Evelina [1 ,2 ]
Ellebaek, Eva [1 ]
Donia, Marco [1 ]
Ehrnrooth, Eva [3 ]
Andersen, Mads H. [1 ,2 ]
Svane, Inge Marie [1 ]
机构：
[1] Herlev Hosp, Dept Oncol, Natl Ctr Canc Immune Therapy CCIT DK, Herlev, Denmark
[2] Herlev Hosp, Dept Oncol, IO Biotech ApS, Herlev, Denmark
[3] IO Biotech ApS, Copenhagen, Denmark
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT535
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
    Antoni Ribas
    Alain Algazi
    Paolo A. Ascierto
    Marcus O. Butler
    Sunandana Chandra
    Michael Gordon
    Leonel Hernandez-Aya
    Donald Lawrence
    Jose Lutzky
    Wilson H. Miller
    Katie M. Campbell
    Bruno Delafont
    Shannon Marshall
    Nancy Mueller
    Caroline Robert
    [J]. Nature Communications, 11
  • [42] PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
    Madore, Jason
    Vilain, Ricardo E.
    Menzies, Alexander M.
    Kakavand, Hojabr
    Wilmott, James S.
    Hyman, Jessica
    Yearley, Jennifer H.
    Kefford, Richard F.
    Thompson, John F.
    Long, Georgina V.
    Hersey, Peter
    Scolyer, Richard A.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (03) : 245 - 253
  • [43] Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL)
    Rodig, Scott J.
    Gjini, Evisa
    Desai, Kaushal
    Jin, Chelsea
    Horak, Christine
    Ruisi, Mary
    Weber, Jeffrey
    Freeman, Gordon J.
    Hodi, F. Stephen
    [J]. CANCER RESEARCH, 2016, 76
  • [44] Correlation of combined positive score of PD-L1 expression and clinical efficacy for advanced esophageal squamous cell carcinoma treated with nivolumab monotherapy
    Mikuni, Hayato
    Yamamoto, Shun
    Sawada, Ryoichi
    Honma, Yoshitaka
    Sekine, Shigeki
    Oguma, Junya
    Saruta, Masayuki
    Daiko, Hiroyuki
    Kato, Ken
    Ishiyama, Koshiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [45] Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
    Miyakoshi, Jun
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Ohe, Yuichiro
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [46] PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy
    Steiniche, T.
    Danielsen, A. Vestergaard
    Wang, Z.
    Feng, Y.
    Nielsen, P. Switten
    Bastholt, L.
    Schmidt, H.
    Svane, I. M.
    Dolled-Filhart, M.
    Emancipator, K.
    Weiner, R.
    Busch-Sorensen, M.
    Zhou, W.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (07) : E319 - E321
  • [47] HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
    Huang, Fu-xue
    Wu, Jun-wan
    Cheng, Xia-qin
    Wang, Jiu-hong
    Wen, Xi-zhi
    Li, Jing-jing
    Zhang, Qiong
    Jiang, Hang
    Ding, Qiu-yue
    Zhu, Xiao-feng
    Zhang, Xiao-shi
    Ding, Ya
    Li, Dan-dan
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
    Lin, Yueh-Min
    Sung, Wen-Wei
    Hsieh, Ming-Ju
    Tsai, Shih-Chen
    Lai, Hung-Wen
    Yang, Shu-Mei
    Shen, Ko-Hong
    Chen, Mu-Kuan
    Lee, Huei
    Yeh, Kun-Tu
    Chen, Chih-Jung
    [J]. PLOS ONE, 2015, 10 (11):
  • [49] Clinical impact of hypothyroidism and PD-L1 SNPs in patients having non-small cell lung cancer treated with nivolumab
    Funazo, Tomoko
    Ozasa, Hiroaki
    Nomizo, Takashi
    Tsuji, Takahiro
    Yasuda, Yuto
    Yoshida, Hironori
    Sakamori, Yuichi
    Nagai, Hiroki
    Hirai, Toyohiro
    Kim, Young Hak
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [50] HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
    Liu, Xiaomei
    Wang, Yuxi
    Zhang, Rong
    Jin, Ting
    Qu, Liangliang
    Jin, Qianwen
    Zheng, Jiasu
    Sun, Jiaqi
    Wu, Ziqing
    Wang, Linxi
    Liu, Tianxu
    Zhang, Yinxu
    Meng, Xiao
    Wang, Ying
    Wei, Ning
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
12345